Rani Therapeutics (NASDAQ:RANI) Price Target Increased to $13.00 by Analysts at HC Wainwright

Posted by Faye Duncan on May 8th, 2024

Rani Therapeutics (NASDAQ:RANI – Free Report) had its price target boosted by HC Wainwright from $12.00 to $13.00 in a research report released on Tuesday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock.

A number of other equities research analysts also recently weighed in on RANI. Wedbush reiterated an outperform rating and issued a $8.00 price target on shares of Rani Therapeutics in a research report on Tuesday, February 6th. Canaccord Genuity Group decreased their target price on shares of Rani Therapeutics from $21.00 to $9.00 and set a buy rating on the stock in a report on Wednesday, March 27th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of Buy and an average price target of $11.75.

View Our Latest Research Report on RANI

Rani Therapeutics Stock Down 1.3 %

Shares of RANI opened at $7.46 on Tuesday. The firm has a market cap of $374.19 million, a P/E ratio of -5.74 and a beta of 0.33. The firm’s 50-day simple moving average is $4.57 and its 200 day simple moving average is $3.47. The company has a debt-to-equity ratio of 0.96, a quick ratio of 6.36 and a current ratio of 6.36. Rani Therapeutics has a 52 week low of $1.82 and a 52 week high of $8.75.

Rani Therapeutics (NASDAQ:RANI – Get Free Report) last posted its quarterly earnings data on Wednesday, March 20th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.04. On average, analysts forecast that Rani Therapeutics will post -0.94 earnings per share for the current year.

Rani Therapeutics Company Profile

(Get Free Report)

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.